Stocklytics Platform
Asset logo for symbol IMVT
Immunovant
IMVT48
$30.57arrow_drop_up0.75%$0.23
Asset logo for symbol IMVT
IMVT48

$30.57

arrow_drop_up0.75%

Performance History

Chart placeholder
Key Stats
Open$30.88
Prev. Close$30.34
EPS-1.88
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$4.43B
PE Ratio-
LOWHIGH
Day Range30.03
30.88
52 Week Range18.82
45.58
Ratios
P/B Ratio6.28
Revenue-
Operating M. %0.00%
Earnings$0.00
Earnings Growth %-22.93%
EBITDA Margin %-
ROE %-52.91%
EPS-1.88

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

Correlated Companies

Price$948.40
Perf. (24h)
arrow_drop_up1.52%$14.26
Market Cap$841.10B
Price$511.53
Perf. (24h)
arrow_drop_up1.42%$7.17
Market Cap$464.20B
Price$149.88
Perf. (24h)
arrow_drop_up0.12%$0.18
Market Cap$360.27B
Price$127.76
Perf. (24h)
arrow_drop_down0.93%-$1.21
Market Cap$326.65B

About Immunovant (IMVT)

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Peter Salzmann M.B.A., M.D.
Headquarters
New York
Employees
164
Exchange
NASDAQ
add Immunovant  to watchlist

Keep an eye on Immunovant

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Immunovant 's (IMVT) price per share?

The current price per share for Immunovant (IMVT) is $30.57. The stock has seen a price change of $0.23 recently, indicating a 0.76% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for Immunovant (IMVT)?

For Immunovant (IMVT), the 52-week high is $45.58, which is 49.1% from the current price. The 52-week low is $18.82, the current price is 62.43% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is Immunovant (IMVT) a growth stock?

Immunovant (IMVT) has shown an average price growth of 0.41% over the past three years. It has received a score of 94 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Immunovant as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Immunovant (IMVT) stock price performance year to date (YTD)?

As of the latest data, Immunovant (IMVT) has a year-to-date price change of -26.14%. Over the past month, the stock has experienced a price change of 14.92%. Over the last three months, the change has been 0.33%. Over the past six months, the figure is -27.64%.

help
Is Immunovant (IMVT) a profitable company?

Immunovant (IMVT) has a net income of -$259.34M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$270.21M. Furthermore, the EBITDA is -$269.98M.

help
What is the market capitalization of Immunovant (IMVT)?

Immunovant (IMVT) has a market capitalization of $4.44B. The average daily trading volume is 1.14M, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level